Ruth He, MD, PhD
@RuthHe12
@Columbiacancer medical oncologist specialized in gastrointestinal cancer and research on liver cancer and biliary cancer. All opinions are mine.
This week, we highlighted research by Narayanan Sadagopan, Hongkun Wang, @ChYin89, @benweinbergmd, @mnoel3232, @ReetuMukherjiMD Xue Geng, @marshalj23, Branden S Moriarity, and @RuthHe12 published in @Nature_NPJ- bit.ly/3GyERvj. Full search: bit.ly/4lsH6zk.
Why #Y90? At ILCA #STW25, we explored evolving strategies in #HCC & #BTCs with top experts in liver cancer. Missed the live discussion on 6 June in Chicago? 🎥Session recordings are now available at ILCA website: ilcalive.org/single-topic-w…
.@benweinbergmd, discussed early results from the phase 2 EXPEL PANC trial (NCT05558982), evaluating BXCL701 plus pembrolizumab (Keytruda) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) after progression on chemotherapy. onclive.com/view/five-unde… via @onclive…
From palliative care a decade ago to first-line curative intent treatment today, #Y90 radiation segmentectomy has been a welcome advancement in #livercancer treatment. 🧩 pubs.rsna.org/doi/epdf/10.11… @RSNA @SIRspecialists @cirsesociety @APASLnews @JSHLiver @myESMO @BCLC_group…
Fresh off the press! @benweinbergmd @ReetuMukherjiMD @mnoel3232 @marshalj23 @RuthHe12 , Thanks for your contribution to this project. Special thanks to Dr.Narayanan Sadagopan, our graduating fellow. nam02.safelinks.protection.outlook.com/?url=https%3A%….
Incredible news! #LR5 (Definite #HCC) criteria of #LIRADS, including #CEUS, are now fully aligned with #OPTN #liver #transplant @UNOSNews @RadiologyACR @chemshift1 optn.transplant.hrsa.gov/media/ojdh4qi1…
Mike, congratulations!
I can't even begin to express what an honor and a privilege it is to work with this group, under @PanCAN 's leadership, and following the path of many amazing predecessors 🙏Thank you a million times over for the opportunity
Cool! 😀
Did a robot case yesterday and this is what my anesthesiologist drew 😅
Stephen, congratulations!
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
Honored and humbled to accept a new role as Division Chief for Hematology & Oncology at Georgetown starting next month. Excited for all that the future holds for @Georgetown @LombardiCancer with the best colleagues one could ask for.
Working closely with my multidisciplinary team, I am excited to serve patients in and around the Big Apple, and begin new research projects in liver and biliary cancers. Please check out our website, which is currently being built and updated regularly: columbiasurgery.org/liver/liver-ca…
It has been 2 m since I joined Columbia. With support of colleagues in Hem/Onc and center for liver disease and transplant, I feel well settled into my new role. For those interested, here is my link: cancer.columbia.edu/profile/aiwu-r…, for new patient: [email protected]
Combining Local Therapy and Immunotherapy in Intermediate Stage HCC - @BeauToskichMD @RuthHe12 @hccconnectinfo @dice_europe @GlobalLiver @EuropeLiver oncodaily.com/blog/beau-bosk… #Immunotherapy #IO #ImmuneOnc #HCC #LiverCancer #Cancer #OncoDaily #Medicine #Oncology #MedEd #MedX
Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for HCC @TheLancet doi.org/10.1016/S0140-… 🔎CheckMate 9DW 👉mOS 23·7 vs 20·6 mo 👉ORR 36 vs 13% 👉Consistent efficacy in ALBI 1 and 2 🧐Great new option for 1st line HCC @myESMO @EASLedu @ILCAnews…
Pts with intermediate stage #HCC may benefit from multimodal strategies, combining IO with locoregional therapies ️ ➡️ Are you updated on the latest data combining IO with locoregional therapies? ➡️ What’s the role of the multidisciplinary team? Get all the answers in this…
Join Us for the 2025 Johns Hopkins Updates in GI Cancers! Don’t miss this power-packed two-day conference on February 7-8, featuring the latest in GI Oncology. I’ll be speaking on PRRT and its role in NET management, alongside an incredible lineup of experts. 📌 Register now:…
Join us tomorrow, Feb 7th, to review @ASCO #GI25 meeting research with the @RueschCenter. @marshalj23, @benweinbergmd, @RuthHe12, @mnoel3232, and @ReetuMukherjiMD will highlight the most compelling abstracts in Colorectal, Pancreatic, Liver, and Upper GI cancers. Register today…
Don’t miss Dr. @jennifermarksmd at the Texas Lung Cancer Conference in Austin, TX! This 2-day CE accredited conference brings together top oncology experts to discuss impactful updates and strategies for treating lung cancer. Learn more: hubs.la/Q0344cdY0 #TexasLung25 #LCSM